Cleveland Clinic clinicians alert other physicians to adverse events related to immune checkpoint inhibitors.
Case report: A 30-year-old patient experiences progressive sensory loss starting with his hands. Collaboration between Cleveland Clinic neurologists and rheumatologists leads to diagnosis and treatment.
Cleveland Clinic rheumatologist Emily Littlejohn, DO, reviews promising new treatments for lupus.
A patient with advanced cutaneous squamous cell carcinoma achieved a near complete response from immunotherapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
T-cell immunophenotyping sheds light on immune response to investigational SL-701-based therapy and promises to inform patient selection to maximize the likelihood of survival benefit.
This novel approach involves injecting supercharged immune cells directly into the tumor cavity in the brain. Encouraging initial findings have set the stage for the launch of phase 2 testing.
Immune toxicity remains a diagnosis of exclusion, and multidisciplinary collaboration remains the cornerstone for early diagnosis and treatment.
New research demonstrates that some immunotherapy drugs are more effective for cancers with certain genetic mutations.
Researchers are investigating whether a combination of immunotherapy with standard chemotherapy and radiation will benefit patients with MSI-high rectal cancer.
A national trial will seek to determine whether maintenance therapy with avelumab and a VEGF tyrosine kinase inhibitor can improve survival among patients with urothelial cancer.